AMI-M1

AML-M1 (Acute Myeloid Leukemia, French-American-British Classification M1)
Definition:
AML-M1 is a subtype of acute myeloid leukemia characterized by a proliferation of myeloblasts (immature white blood cells) with minimal maturation. It is classified under the FAB (French-American-British) system as M1, which means “without maturation.”

Key Features:

Bone marrow and blood contain ≥ 20% myeloblasts with minimal differentiation into mature cells.

Myeloblasts typically lack significant granulocytic maturation beyond the blast stage.

Common markers: CD13, CD33 are usually positive, HLA-DR often positive.

Clinical symptoms: fatigue, anemia, infections, bleeding tendencies due to bone marrow failure.

Diagnosis:

Bone marrow biopsy showing ≥ 20% myeloblasts.

Immunophenotyping showing expression of myeloid markers such as CD13, CD33.

Cytogenetic and molecular testing to identify mutations (e.g., FLT3, NPM1) that guide prognosis and treatment.

Treatment:

Typically involves intensive chemotherapy aimed at inducing remission.

May include consolidation chemotherapy and hematopoietic stem cell transplantation in eligible patients.

Prognosis:

Prognosis depends on various factors including genetic mutations, patient age, and response to treatment.

AML-M1 has a variable prognosis; patients with favorable mutations have better outcomes.